A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer

Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Li Benjamin C. [verfasserIn] Perkins Stephanie M. [verfasserIn] Phillips Sharon E. [verfasserIn] Martin Sara F. [verfasserIn] Hsieh Samantha [verfasserIn] Shinohara Eric T. [verfasserIn] Stavas Mark J. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	end of life chemotherapy radiation utilization palliative care

Übergeordnetes Werk:	In: Forum of Clinical Oncology - Sciendo, 2015, 11(2020), 1, Seite 29-38
Übergeordnetes Werk:	volume:11 ; year:2020 ; number:1 ; pages:29-38

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.2478/fco-2019-0013

Katalog-ID:	DOAJ02881228X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ02881228X
003	DE-627
005	20230307131151.0
007	cr uuu---uuuuu
008	230226s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2478/fco-2019-0013 \|2 doi
035			\|a (DE-627)DOAJ02881228X
035			\|a (DE-599)DOAJ562a7f5dcaac43bd86cf146b1d739ee6
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Li Benjamin C. \|e verfasserin \|4 aut
245	1	2	\|a A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC).
650		4	\|a end of life
650		4	\|a chemotherapy
650		4	\|a radiation
650		4	\|a utilization
650		4	\|a palliative care
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Perkins Stephanie M. \|e verfasserin \|4 aut
700	0		\|a Phillips Sharon E. \|e verfasserin \|4 aut
700	0		\|a Martin Sara F. \|e verfasserin \|4 aut
700	0		\|a Hsieh Samantha \|e verfasserin \|4 aut
700	0		\|a Shinohara Eric T. \|e verfasserin \|4 aut
700	0		\|a Stavas Mark J. \|e verfasserin \|4 aut
773	0	8	\|i In \|t Forum of Clinical Oncology \|d Sciendo, 2015 \|g 11(2020), 1, Seite 29-38 \|w (DE-627)663847516 \|w (DE-600)2616865-0 \|x 1792362X \|7 nnns
773	1	8	\|g volume:11 \|g year:2020 \|g number:1 \|g pages:29-38
856	4	0	\|u https://doi.org/10.2478/fco-2019-0013 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/562a7f5dcaac43bd86cf146b1d739ee6 \|z kostenfrei
856	4	0	\|u https://doi.org/10.2478/fco-2019-0013 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1792-362X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 11 \|j 2020 \|e 1 \|h 29-38

Indexfelder

author_variant	l b c lbc p s m psm p s e pse m s f msf h s hs s e t set s m j smj
matchkey_str	article:1792362X:2020----::rveoceohrpadaiteayerhedfienniiulwtmts
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	10.2478/fco-2019-0013 doi (DE-627)DOAJ02881228X (DE-599)DOAJ562a7f5dcaac43bd86cf146b1d739ee6 DE-627 ger DE-627 rakwb eng RC254-282 Li Benjamin C. verfasserin aut A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC). end of life chemotherapy radiation utilization palliative care Neoplasms. Tumors. Oncology. Including cancer and carcinogens Perkins Stephanie M. verfasserin aut Phillips Sharon E. verfasserin aut Martin Sara F. verfasserin aut Hsieh Samantha verfasserin aut Shinohara Eric T. verfasserin aut Stavas Mark J. verfasserin aut In Forum of Clinical Oncology Sciendo, 2015 11(2020), 1, Seite 29-38 (DE-627)663847516 (DE-600)2616865-0 1792362X nnns volume:11 year:2020 number:1 pages:29-38 https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/article/562a7f5dcaac43bd86cf146b1d739ee6 kostenfrei https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/toc/1792-362X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 29-38
spelling	10.2478/fco-2019-0013 doi (DE-627)DOAJ02881228X (DE-599)DOAJ562a7f5dcaac43bd86cf146b1d739ee6 DE-627 ger DE-627 rakwb eng RC254-282 Li Benjamin C. verfasserin aut A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC). end of life chemotherapy radiation utilization palliative care Neoplasms. Tumors. Oncology. Including cancer and carcinogens Perkins Stephanie M. verfasserin aut Phillips Sharon E. verfasserin aut Martin Sara F. verfasserin aut Hsieh Samantha verfasserin aut Shinohara Eric T. verfasserin aut Stavas Mark J. verfasserin aut In Forum of Clinical Oncology Sciendo, 2015 11(2020), 1, Seite 29-38 (DE-627)663847516 (DE-600)2616865-0 1792362X nnns volume:11 year:2020 number:1 pages:29-38 https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/article/562a7f5dcaac43bd86cf146b1d739ee6 kostenfrei https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/toc/1792-362X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 29-38
allfields_unstemmed	10.2478/fco-2019-0013 doi (DE-627)DOAJ02881228X (DE-599)DOAJ562a7f5dcaac43bd86cf146b1d739ee6 DE-627 ger DE-627 rakwb eng RC254-282 Li Benjamin C. verfasserin aut A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC). end of life chemotherapy radiation utilization palliative care Neoplasms. Tumors. Oncology. Including cancer and carcinogens Perkins Stephanie M. verfasserin aut Phillips Sharon E. verfasserin aut Martin Sara F. verfasserin aut Hsieh Samantha verfasserin aut Shinohara Eric T. verfasserin aut Stavas Mark J. verfasserin aut In Forum of Clinical Oncology Sciendo, 2015 11(2020), 1, Seite 29-38 (DE-627)663847516 (DE-600)2616865-0 1792362X nnns volume:11 year:2020 number:1 pages:29-38 https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/article/562a7f5dcaac43bd86cf146b1d739ee6 kostenfrei https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/toc/1792-362X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 29-38
allfieldsGer	10.2478/fco-2019-0013 doi (DE-627)DOAJ02881228X (DE-599)DOAJ562a7f5dcaac43bd86cf146b1d739ee6 DE-627 ger DE-627 rakwb eng RC254-282 Li Benjamin C. verfasserin aut A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC). end of life chemotherapy radiation utilization palliative care Neoplasms. Tumors. Oncology. Including cancer and carcinogens Perkins Stephanie M. verfasserin aut Phillips Sharon E. verfasserin aut Martin Sara F. verfasserin aut Hsieh Samantha verfasserin aut Shinohara Eric T. verfasserin aut Stavas Mark J. verfasserin aut In Forum of Clinical Oncology Sciendo, 2015 11(2020), 1, Seite 29-38 (DE-627)663847516 (DE-600)2616865-0 1792362X nnns volume:11 year:2020 number:1 pages:29-38 https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/article/562a7f5dcaac43bd86cf146b1d739ee6 kostenfrei https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/toc/1792-362X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 29-38
allfieldsSound	10.2478/fco-2019-0013 doi (DE-627)DOAJ02881228X (DE-599)DOAJ562a7f5dcaac43bd86cf146b1d739ee6 DE-627 ger DE-627 rakwb eng RC254-282 Li Benjamin C. verfasserin aut A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC). end of life chemotherapy radiation utilization palliative care Neoplasms. Tumors. Oncology. Including cancer and carcinogens Perkins Stephanie M. verfasserin aut Phillips Sharon E. verfasserin aut Martin Sara F. verfasserin aut Hsieh Samantha verfasserin aut Shinohara Eric T. verfasserin aut Stavas Mark J. verfasserin aut In Forum of Clinical Oncology Sciendo, 2015 11(2020), 1, Seite 29-38 (DE-627)663847516 (DE-600)2616865-0 1792362X nnns volume:11 year:2020 number:1 pages:29-38 https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/article/562a7f5dcaac43bd86cf146b1d739ee6 kostenfrei https://doi.org/10.2478/fco-2019-0013 kostenfrei https://doaj.org/toc/1792-362X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 29-38
language	English
source	In Forum of Clinical Oncology 11(2020), 1, Seite 29-38 volume:11 year:2020 number:1 pages:29-38
sourceStr	In Forum of Clinical Oncology 11(2020), 1, Seite 29-38 volume:11 year:2020 number:1 pages:29-38
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	end of life chemotherapy radiation utilization palliative care Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Forum of Clinical Oncology
authorswithroles_txt_mv	Li Benjamin C. @@aut@@ Perkins Stephanie M. @@aut@@ Phillips Sharon E. @@aut@@ Martin Sara F. @@aut@@ Hsieh Samantha @@aut@@ Shinohara Eric T. @@aut@@ Stavas Mark J. @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	663847516
id	DOAJ02881228X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ02881228X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307131151.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2478/fco-2019-0013</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ02881228X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ562a7f5dcaac43bd86cf146b1d739ee6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Li Benjamin C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC).</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">end of life</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">radiation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">utilization</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">palliative care</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Perkins Stephanie M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Phillips Sharon E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Sara F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hsieh Samantha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shinohara Eric T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stavas Mark J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Forum of Clinical Oncology</subfield><subfield code="d">Sciendo, 2015</subfield><subfield code="g">11(2020), 1, Seite 29-38</subfield><subfield code="w">(DE-627)663847516</subfield><subfield code="w">(DE-600)2616865-0</subfield><subfield code="x">1792362X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:29-38</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2478/fco-2019-0013</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/562a7f5dcaac43bd86cf146b1d739ee6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2478/fco-2019-0013</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1792-362X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">29-38</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Li Benjamin C.
spellingShingle	Li Benjamin C. misc RC254-282 misc end of life misc chemotherapy misc radiation misc utilization misc palliative care misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer
authorStr	Li Benjamin C.
ppnlink_with_tag_str_mv	@@773@@(DE-627)663847516
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	1792362X
topic_title	RC254-282 A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer end of life chemotherapy radiation utilization palliative care
topic	misc RC254-282 misc end of life misc chemotherapy misc radiation misc utilization misc palliative care misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc end of life misc chemotherapy misc radiation misc utilization misc palliative care misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc end of life misc chemotherapy misc radiation misc utilization misc palliative care misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Forum of Clinical Oncology
hierarchy_parent_id	663847516
hierarchy_top_title	Forum of Clinical Oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)663847516 (DE-600)2616865-0
title	A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer
ctrlnum	(DE-627)DOAJ02881228X (DE-599)DOAJ562a7f5dcaac43bd86cf146b1d739ee6
title_full	A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer
author_sort	Li Benjamin C.
journal	Forum of Clinical Oncology
journalStr	Forum of Clinical Oncology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	29
author_browse	Li Benjamin C. Perkins Stephanie M. Phillips Sharon E. Martin Sara F. Hsieh Samantha Shinohara Eric T. Stavas Mark J.
container_volume	11
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Li Benjamin C.
doi_str_mv	10.2478/fco-2019-0013
author2-role	verfasserin
title_sort	review of chemotherapy and radiotherapy near the end of life in individuals with metastatic non-small cell lung cancer
callnumber	RC254-282
title_auth	A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer
abstract	Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC).
abstractGer	Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC).
abstract_unstemmed	Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC).
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer
url	https://doi.org/10.2478/fco-2019-0013 https://doaj.org/article/562a7f5dcaac43bd86cf146b1d739ee6 https://doaj.org/toc/1792-362X
remote_bool	true
author2	Perkins Stephanie M. Phillips Sharon E. Martin Sara F. Hsieh Samantha Shinohara Eric T. Stavas Mark J.
author2Str	Perkins Stephanie M. Phillips Sharon E. Martin Sara F. Hsieh Samantha Shinohara Eric T. Stavas Mark J.
ppnlink	663847516
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.2478/fco-2019-0013
callnumber-a	RC254-282
up_date	2024-07-03T19:34:05.828Z
_version_	1803587677931438080
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ02881228X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307131151.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2478/fco-2019-0013</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ02881228X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ562a7f5dcaac43bd86cf146b1d739ee6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Li Benjamin C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC).</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">end of life</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">radiation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">utilization</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">palliative care</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Perkins Stephanie M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Phillips Sharon E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Sara F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hsieh Samantha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shinohara Eric T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stavas Mark J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Forum of Clinical Oncology</subfield><subfield code="d">Sciendo, 2015</subfield><subfield code="g">11(2020), 1, Seite 29-38</subfield><subfield code="w">(DE-627)663847516</subfield><subfield code="w">(DE-600)2616865-0</subfield><subfield code="x">1792362X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:29-38</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2478/fco-2019-0013</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/562a7f5dcaac43bd86cf146b1d739ee6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2478/fco-2019-0013</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1792-362X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">29-38</subfield></datafield></record></collection>
score	7.4006395

Nicht das Richtige dabei?

Schreiben Sie uns!

A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?